
Feb 5 (Reuters) - Bristol-Myers Squibb Co BMY.N:
BRISTOL MYERS Q4 ADJUSTED EPS INCLUDES NET IMPACT OF $-0.60 DUE TO ACQUIRED IPRD CHARGES & LICENSING INCOME
BRISTOL MYERS Q4 REVENUE $12.5 BILLION VERSUS IBES ESTIMATE $12.28 BILLION
BRISTOL MYERS OUTLOOK 2026 REVENUE ABOUT $46.0 BILLION TO $47.5 BILLION VERSUS IBES ESTIMATE $44.16 BILLION
BRISTOL MYERS Q4 ADJUSTED EPS $1.26 VERSUS IBES ESTIMATE $1.12
BRISTOL MYERS OUTLOOK 2026 ADJUSTED EPS $6.05 TO $6.35 VERSUS IBES ESTIMATE $6.02
BRISTOL MYERS OUTLOOK 2026 ELIQUIS WW REVENUE GROWTH 10% - 15%